Since the establishment of CSF and imaging biomarkers of amyloid beta and tau in 2011 by the National Institute on Aging (NIA) and the Alzheimer’s Association (AA) (94–96), and the resulting profiling via the A/T/N framework in 2018 (6), no major changes in the official clinical criteria for diagnosis and staging of AD have been made. The gene discussed is MAPT; the disease is Alzheimer disease.